Comparative Efficacy of Ursodeoxycholic Acid and Fibrates in Primary Biliary Cholangitis

A 2025 umbrella meta-analysis synthesizes evidence from 23 prior meta-analyses covering 45 unique randomized controlled trials and 3,276 patients with primary biliary cholangitis. The document, authored by Jian Zhang and shared under a CC-BY-4.0 license, evaluates the biochemical response and safety of ursodeoxycholic acid, fibrates, and their combination therapy. It was last updated on 2026-05-25.

Use Cases

• Conducting secondary analysis of biochemical response rates (ALP, bilirubin) based on the aggregated meta-analysis results
• Assessing the safety profile of combination therapy based on reported adverse event rates (12%–18%)
• Evaluating methodological quality and overlap in existing meta-analyses based on AMSTAR 2 and corrected covered area (CCA) metrics
• Informing clinical guideline development for primary biliary cholangitis based on synthesized efficacy evidence

Strengths

• Aggregates findings from 23 meta-analyses and 45 unique randomized controlled trials
• Includes data on 3,276 patients after deduplication
• Reports specific biochemical outcomes with confidence intervals (e.g., ALP MD -85.4 U/L)

Limitations

• The dataset is a 23.3 KB DOCX document summarizing results, not the underlying trial data
• Row count and column-level documentation for any potential tabular data within the file are unknown
• Evidence on long-term outcomes like survival and transplant-free survival is noted as insufficient

Provenance

Source

figshare

Collection Method

Systematic review and umbrella meta-analysis of existing meta-analyses.

Time Range

Meta-analyses searched from database inception to 2025.

Freshness

Last updated 2026-05-25 04:33:17